HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $6 price target.
June 01, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearside Biomedical receives a reiterated Buy rating from HC Wainwright & Co. analyst Yi Chen, with a maintained $6 price target.
The Buy rating and maintained $6 price target by HC Wainwright & Co. analyst Yi Chen indicates a positive outlook for Clearside Biomedical. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100